To access this element change to forms mode OFF
Grant Award View - GA40804
The AIM2 Study: Genomically Guided Novel Combination Treatment of Mantle...
GA ID:
GA40804
Agency:
Department of Health and Aged Care
Approval Date:
29-Mar-2019
Publish Date:
26-Apr-2019
Category:
Medical Research
Grant Term:
1-Apr-2019 to 31-Mar-2023
Value (AUD):
$2,005,391.40
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DoHAC 18/19 1.1 Health and Medical Research
Grant Program:
2018_MRFF Rare Cancers Rare Diseases, Unmet Need_commencing_2018
Grant Activity:
The AIM2 Study: Genomically Guided Novel Combination Treatment of Mantle Cell Lymphoma
Purpose:
Mantle Cell Lymphoma (MCL) has short survival and new treatments are urgently required. Our group pioneered the ibrutinib-venetoclax combination in MCL in the AIM1 study, reporting a 71 percent complete remission rate. In this proposal, we will use the knowledge from AIM to identify resistant patients apriori, and introduce the new drug navitoclax. For all patients, we will include the monoclonal anti-CD20 antibody. These results will be compared against the results of the AIM1 study.
GO ID:
GO Title:
Medical Research Future Fund Clinical Trials Activity – Rare Cancers, Rare Diseases and Unmet Need Grant Opportunity
Internal Reference ID:
MRF1170100
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
University of Melbourne
Recipient ABN:
84 002 705 224
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
NSW, VIC, SA, QLD
Postcode:
Multiple
Country:
AUSTRALIA